The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.
History of Oncolytic Viruses: Genesis to Genetic Engineering
Open accessAbstract
Since the turn of the nineteenth century, when their existence was first recognized, viruses have attracted considerable interest as possible agents of tumor destruction. Early case reports emphasized regression of cancers during naturally acquired virus infections, providing the basis for clinical trials where body fluids containing human or animal viruses were used to transmit infections to cancer patients. Most often the viruses were arrested by the host immune system and failed to impact tumor growth, but sometimes, in immunosuppressed patients, infection persisted and tumors regressed, although morbidity as a result of the infection of normal tissues was unacceptable. With the advent of rodent models and new methods for virus propagation, there were numerous attempts through the 1950s and 1960s to force the evolution of viruses with greater tumor specificity, but success was limited and many researchers abandoned the field. Technology employing reverse genetics later brought about a renewal of interest in virotherapy that allowed the generation of more potent, tumor-specific oncolytics. Here, examination of early oncolytic virotherapy before genetic engineering serves to highlight tremendous advances, yet also hints at ways to penetrate host immune defenses, a significant remaining challenge in modern virotherapy research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Viral RNA-dependent DNA Polymerase: RNA-dependent DNA Polymerase in Virions of RNA Tumour Viruses
BALTIMORE, D. (1970) · Nature · doi:10.1038/2261209a0 · Cited by 2,068
Farber, S., Diamond, L. K., Mercer, R. D., Sylvester, R. F., & Wolff, J. A. (1948) · New England Journal of Medicine · doi:10.1056/nejm194806032382301 · Cited by 1,806
Three-Dimensional Structure of Poliovirus at 2.9 Å Resolution
Hogle, J. M., Chow, M., & Filman, D. J. (1985) · Science · doi:10.1126/science.2994218 · Cited by 1,260
Experimental Therapy of Human Glioma by Means of a Genetically Engineered Virus Mutant
Martuza, R. L., Malick, A., Markert, J. M., Ruffner, K. L., & Coen, D. M. (1991) · Science · doi:10.1126/science.1851332 · Cited by 1,050
(1952) · Cancer Research · Cited by 987
Edward Jenner and the History of Smallpox and Vaccination
Riedel, S. (2005) · Baylor University Medical Center Proceedings · doi:10.1080/08998280.2005.11928028 · Cited by 964
Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., & Bell, J. C. (2000) · Nature Medicine · doi:10.1038/77558 · Cited by 815
Cloned Poliovirus Complementary DNA Is Infectious in Mammalian Cells
Racaniello, V. R., & Baltimore, D. (1981) · Science · doi:10.1126/science.6272391 · Cited by 696
Radiation oncology: a century of achievements
Bernier, J., Hall, E. J., & Giaccia, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1451 · Cited by 628
The Growth in Vitro of Single Isolated Tissue Cells
(1948) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/9.3.229 · Cited by 588
Anderson, W. (1992) · Science · doi:10.1126/science.1589762 · Cited by 557
Recent progress in the battle between oncolytic viruses and tumours
Parato, K. A., Senger, D., Forsyth, P. A. J., & Bell, J. C. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1750 · Cited by 536
Prospects for Human Gene Therapy
Anderson, W. F. (1984) · Science · doi:10.1126/science.6093246 · Cited by 533
McFadden, G. (2005) · Nature Reviews Microbiology · doi:10.1038/nrmicro1099 · Cited by 523
China Approves World's First Oncolytic Virus Therapy For Cancer Treatment
Garber, K. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj111 · Cited by 489
Replicative adenoviruses for cancer therapy
Alemany, R., Balagué, C., & Curiel, D. T. (2000) · Nature Biotechnology · doi:10.1038/77283 · Cited by 421
On a Form of Chronic Joint Disease in Children
Still, G. F., & Garrod, A. E. (1897) · Journal of the Royal Society of Medicine · doi:10.1177/095952879708000106 · Cited by 418
REGRESSION OF BURKITT'S LYMPHOMA IN ASSOCIATION WITH MEASLES INFECTION
Bluming, A., & Ziegler, J. (1971) · The Lancet · doi:10.1016/s0140-6736(71)92086-1 · Cited by 410
On a Form of Chronic Joint Disease in Children.
Still, G. F. (1897) · PubMed Central · Cited by 396
FREI, E., KARON, M., LEVIN, R. H., FREIREICH, E. J., TAYLOR, R. J., HANANIAN, J., SELAWRY, O., HOLLAND, J. F., HOOGSTRATEN, B., WOLMAN, I. J., et al. (1965) · Blood · doi:10.1182/blood.v26.5.642.642 · Cited by 325
Dingli, D., Peng, K.-W., Harvey, M. E., Greipp, P. R., O'Connor, M. K., Cattaneo, R., Morris, J. C., & Russell, S. J. (2004) · Blood · doi:10.1182/blood-2003-07-2233 · Cited by 320
Self-citationOncolytic viral therapies – the clinical experience
Aghi, M., & Martuza, R. L. (2005) · Oncogene · doi:10.1038/sj.onc.1209037 · Cited by 288
Induction of Both Thymidine and Deoxycytidine Kinase Activity by Herpes Viruses
Jamieson, A. T., Gentry, G. A., & Subak-Sharpe, J. H. (1974) · Journal of General Virology · doi:10.1099/0022-1317-24-3-465 · Cited by 288
Sur un microbe invisible antagoniste des bacilles dysenteriques
D'Herelle, M. F. (1961) · Americanae (AECID Library) · Cited by 288
Parrish, C. R., & Kawaoka, Y. (2005) · Annual Review of Microbiology · doi:10.1146/annurev.micro.59.030804.121059 · Cited by 271
Nh, P., PHILIPS, M., & Wf, W. (1964) · PubMed · Cited by 263
Rescue and propagation of fully retargeted oncolytic measles viruses
Nakamura, T., Peng, K.-W., Harvey, M., Greiner, S., Lorimer, I. A. J., James, C. D., & Russell, S. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1060 · Cited by 252
Self-citationCRAWFORD, J. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92370-8 · Cited by 239
Newcastle disease virus (NDV): brief history of its oncolytic strains
Sinkovics, J. G., & Horvath, J. C. (2000) · Journal of Clinical Virology · doi:10.1016/s1386-6532(99)00072-4 · Cited by 219
Points to Consider Response with Clinical Protocol, July 6, 1990
Anderson, W. F., Blaese, R. M., & Culver, K. (1990) · Human Gene Therapy · doi:10.1089/hum.1990.1.3-331 · Cited by 218
Treatment of human cancer with mumps virus
Asada, T. (1974) · Cancer · doi:10.1002/1097-0142(197412)34:6<1907::aid-cncr2820340609>3.0.co;2-4 · Cited by 213
Therapy of Choriocarcinoma and Related Trophoblastic Tumors with Folic Acid and Purine Antagonists
Li, M. C., Hertz, R., & Bergenstal, D. M. (1958) · New England Journal of Medicine · doi:10.1056/nejm195807102590204 · Cited by 189
Formaldehyde Treatment and Safety Testing of Experimental Poliomyelitis Vaccines
Salk, J. E., Krech, U., Youngner, J. S., Bennett, B. L., Lewis, L. J., & Bazeley, P. L. (1954) · American Journal of Public Health and the Nations Health · doi:10.2105/ajph.44.5.563 · Cited by 183
Homotransplantation of Human Cell Lines
Southam, C. M., Moore, A. E., & Rhoads, C. P. (1957) · Science · doi:10.1126/science.125.3239.158 · Cited by 163
Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides
Peng, K.-W., Facteau, S., Wegman, T., O'Kane, D., & Russell, S. J. (2002) · Nature Medicine · doi:10.1038/nm0502-527 · Cited by 162
Self-citationShafren, D. R., Au, G. G., Nguyen, T. P., Newcombe, N. G., Haley, E. S., Beagley, L., Johansson, E., Hersey, P., & Barry, R. D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-0690-3 · Cited by 158
Reovirus as a novel oncolytic agent
Norman, K. L., & Lee, P. W. K. (2000) · Journal of Clinical Investigation · doi:10.1172/jci9871 · Cited by 124
Oncolytic adenoviruses – selective retargeting to tumor cells
Mathis, J. M., Stoff‐Khalili, M. A., & Curiel, D. T. (2005) · Oncogene · doi:10.1038/sj.onc.1209044 · Cited by 122
Nakamura, T., Peng, K.-W., Vongpunsawad, S., Harvey, M. E., Mizuguchi, H., Hayakawa, T., Cattaneo, R., & Russell, S. J. (2004) · Nature Biotechnology · doi:10.1038/nbt942 · Cited by 118
Self-citationDIVISION OF MICROBIOLOGY: PRESENT STATUS OF ONCOLYTIC VIRUS STUDIES*
Southam, C. M. (1960) · Transactions of the New York Academy of Sciences · doi:10.1111/j.2164-0947.1960.tb00739.x · Cited by 115
Genesis of endometrial carcinoma.II. Cases 19 to 35 years old
Sommers, S. C., Hertig, A. T., & Bengloff, H. (1949) · Cancer · doi:10.1002/1097-0142(194911)2:6<943::aid-cncr2820020602>3.0.co;2-p · Cited by 96
Use of Viruses as Carriers of Added Genetic Information
Rogers, S., & Pfuderer, P. (1968) · Nature · doi:10.1038/219749a0 · Cited by 95
Cultivation of Poliomyelitis Virus in Cultures of Human Foreskin and Embryonic Tissues.
Th, W., Robbins, F. C., & Enders, J. F. (1949) · Experimental Biology and Medicine · doi:10.3181/00379727-72-17359 · Cited by 92
Oncolytic virotherapy for cancer treatment: challenges and solutions
Davis, J. J., & Fang, B. (2005) · The Journal of Gene Medicine · doi:10.1002/jgm.800 · Cited by 88
A history of neuraxial administration of local analgesics and opioids
Brill, S., Gürman, G., & Fisher, A. (2003) · European Journal of Anaesthesiology · doi:10.1097/00003643-200309000-00002 · Cited by 86
A history of neuraxial administration of local analgesics and opioids
Brill, S., Gürman, G., & Fisher, A. (2005) · European Journal of Anaesthesiology · doi:10.1017/s026502150300111x · Cited by 79
VIRUSES IN THE TREATMENT OF CANCER
Csatáry, L. K. (1971) · The Lancet · doi:10.1016/s0140-6736(71)92788-7 · Cited by 65
Oncolytic measles viruses for cancer therapy
Nakamura, T., & Russell, S. J. (2004) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.4.10.1685 · Cited by 65
Self-citationReplicating vectors for gene therapy of cancer: risks, limitations and prospects
Russell, S. J. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90477-4 · Cited by 56
Self-citationReplicating vectors for cancer therapy: a question of strategy.
Russell, S. J. (1994) · PubMed · Cited by 53
Self-citationReengineering paramyxovirus tropism
Hadac, E. M., Peng, K.-W., Nakamura, T., et al. (2004) · Virology · doi:10.1016/j.virol.2004.08.036 · Cited by 49
MASSIVE PREDNISONE AND PREDNISOLONE THERAPY IN LEUKEMIA AND LYMPHOMAS IN THE ADULT††
Hill, J. M., Marshall, G. J., & Falco, D. (1956) · Journal of the American Geriatrics Society · doi:10.1111/j.1532-5415.1956.tb00846.x · Cited by 33
Herpes simplex virus-based vectors for the treatment of cancer and neurodegenerative disease.
Latchman, D. S. (2005) · PubMed · Cited by 23
Homotransplantation of human cell lines.
Southam, C. M. (1958) · PubMed · Cited by 19
HISTORY AND PROSPECTS OF IMMUNOTHERAPY OF CANCER: AN INTRODUCTION
Southam, C. M. (1976) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1976.tb41687.x · Cited by 12
Campbell, S. A., & Gromeier, M. (2005) · Oncology Research and Treatment · doi:10.1159/000084010 · Cited by 10
Attenuated mumps virus therapy of carcinoma of the maxillary sinus
Sato, M., Urade, M., SAKUDA, M., Shirasuna, K., Yoshida, H., Maeda, N., Yanagawa, T., Morimoto, M., Yura, Y., Miyazaki, T., et al. (1979) · International Journal of Oral Surgery · doi:10.1016/s0300-9785(79)80020-4 · Cited by 7
Viruses in Treatment of Cancer
(1957) · BMJ · doi:10.1136/bmj.2.5059.1481 · Cited by 5
Cited by
Russell, S. J., Peng, K.-W., & Bell, J. C. (2012) · Nature Biotechnology · doi:10.1038/nbt.2287 · Cited by 1,428
Self-citationOncolytic virus therapy: A new era of cancer treatment at dawn
Fukuhara, H., Ino, Y., & Todo, T. (2016) · Cancer Science · doi:10.1111/cas.13027 · Cited by 774
Going viral with cancer immunotherapy
Lichty, B. D., Breitbach, C. J., Stojdl, D. F., & Bell, J. C. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3770 · Cited by 581
Oncolytic virotherapy: basic principles, recent advances and future directions
Lin, D., Shen, Y., & Liang, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01407-6 · Cited by 459
Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded
Cattaneo, R., Miest, T., Shashkova, E. V., & Barry, M. A. (2008) · Nature Reviews Microbiology · doi:10.1038/nrmicro1927 · Cited by 373
Metadata
- Authors
- Kelly, E., & Russell, S. J.
- Venue
- Molecular Therapy
- Publisher
- Elsevier BV
- Published
- 2007-04
- Volume
- 15
- Issue
- 4
- Pages
- 651-659
- ISSN
- 1525-0016 (ISSN-L)
- OpenAlex
- W2063512646
- Cited by
- 763
- References
- 58
- FWCI
- 13.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.